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Acute renal failure (ARF) is a common clinical problem with increasing incidence, serious 
consequences, unsatisfactory therapeutic options and enormous financial burden to society. 
The aim is to investigate the role of human umbilical cord blood (HUCB) derived 
mesenchymal (MSCs) and CD34+ hematopoietic stem cell therapy in repair of renal damage 
and improvement of renal function in cisplatin-induced ARF model. Forty four rats were 
divided into 4 equal groups. ARF was induced in 3 groups using cisplatin and was confirmed 
by an increase in serum urea and creatinine levels after 5 days. On the same day, 2 groups were 
injected via the tail vein by either MSCs (1x106 cells/rat) or CD34+ hematopoietic cells (5 
x105 cells/rat). The third group received intravenous injection of phosphate buffer 
saline and served as positive control, while the last group was normal control. Renal functions 
were followed up every 4 days. Thirty-three days after initiation of cisplantin injection, rats 
were sacrificed, kidneys were extracted for histopathological and immunohistochemical 
examination for detection of human specific anti-vimentin monoclonal mouse anti-body to 
investigate homing of HUCB stem cells into the damaged renal tissue. Treatment with MSCs 
and CD34+ cells significantly decreased both serum urea and creatinine induced by cisplatin 
administration with concomitant improvement in the degree of necrotic and degenerative 
changes. There was no significant difference in these parameters between MSCs and CD 34+ 
stem cells treated groups. There was positive reaction for human specific anti-vimentin in 
88.9% of animals in MSCs treated rats versus 87.5% in CD34+ cells treated rats. HUCB 
derived CD 34+ and MSCs accelerate regeneration of renal tubular epithelial cells and lead to 
reduction of progressive renal injury in cisplatin-induced acute renal failure rats. 
	  





The clinical condition of ARF is a common cause of 
morbidity and mortality and no satisfactory 
management is currently available (Bellomo et al., 
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2004). In the early 2000s, pluripotent bone marrow–
derived stem cells were thought to contribute directly to 
regeneration of the kidney (Kale et al., 2003). Togel et 
al., (2005) demonstrated that administration of bone 
marrow derived stem cell (BMSC) significantly 
improved renal function in the ischemia/reperfusion 
model. Also, Bi et al., (2007) demonstrated that transfer 
of BMSC into the peritoneal cavity accelerates 
recovery from cisplatin-induced ARF in mice. 
 There are many problems with bone marrow cell 
transplantation, such as the limitation of cell number, 
the donor’s physical responsibility and the prevention 
of rejection (Nonome et al., 2005). Human umbilical 








cord blood (HUCB), however, can be collected without 
any harm to the newborn infant and has been found to 
be multipotent and cause fewer episodes of rejection 
because of the relative immaturity of its cells (Lewis 
2002). Umbilical cord blood (UCB) contains 
circulating stem /progenitor cells and its cellular 
contents are known to be quite distinct (Kakinuma et 
al., 2003). HUCB cells have also been reported to 
differentiate into a variety of cell types such as 
cartilage, muscle (Erices et al., 2000), bone and nerve 
cells (Goodwin et al., 2001) and hepatocytes 
(Kakinuma et al., 2003). 
 To the best of our knowledge, the application of 
HUCB derived CD34+ cells in treating ARF has not 
been reported. However, the application of HUCB 
MSCs in treating ARF has been reported in few studies 
(Cao et al., 2010 and Morigi et al., 2010).  In a previous 
study, we compared the effects of HUCB progenitor 
cells and mononuclear cells (MNCs) on glycerol 
induced ARF and found that, HUCB CD34+ cells and 
HUCB MNCs improved renal function of nephrotoxic 
kidney with superiority to the HUCB MNCs (Mohamed 
et al., 2011). 
 Therefore, the applications of HUCB stem cells 
should be further expanded and may serve as an 
excellent alternative to BMSC for cell transplantation 
in ARF. In this study we will investigate the role of 
HUCB MSCs and CD34+ hematopoietic stem cells 
therapy in repair of renal damage and improvement of 
renal function in cisplatin-induced ARF. Also, we will 
compare the regenerative effect of MSCs and CD34+ 
hematopoietic stem cells to suggest the better cell type. 
 
MATERIALS AND METHODS 
 
Animals:  
Forty four female Wistar rats, aged 8-12 weeks with 
average weight of 148.6 ± 19.5 gm were randomly 
selected in this study. All rats were housed in small 
cages at room temperature. They were maintained at 
a 12-h day and night cycle. They were acclimatized for 
one week and kept with free access to standard pellet 
animal diet and tap water. 
 
Rats were randomly divided into four equal groups 
(11 animals each): group I (GI) Negative control 
group: without any intervention, group II (GII) 
Positive control group: was subjected to 
induction of ARF with intraperitoneal cisplatin 7 
mg/kg (Vaziri et al., 1994) then received 
intravenous injection of phosphate buffer saline, 
groups III (GIII) MSC group, and IV (GIV) 
CD34+ group: were subjected to induction of 
renal failure as in group II, then to 
transplantation of either HUCB MSCs in a dose 
of 1x106 cells/ rat, or to  HUCB CD34+ cells in a 
dose of 5x105 cells/ rat after five days through 




Renal function was assessed by measuring serum urea 
and creatinine levels. Blood samples were obtained 
from retro-orbital sinuses of the rats before induction of 
ARF (basal level), 5 days after induction to confirm its 
occurrence and then measured every 4 days afterwards 
until the animals were sacrificed 33 days after 
induction of ARF by decapitation under ether 
anaesthesia. Kidneys were isolated and prepared for 
histopathological and immunohistochemical 
examination.  
 
Measurement of Serum Urea and Creatinine Levels:  
Blood samples were centrifuged at 3000 rpm for 10 
min and the supernatant was stored at -70°C for later 
determination of serum urea and creatinine which were 
done by vitro Scient    colorimetric kits (Vitro Scient, 
Inshas Industrial Zone, Belbis, Sharkia, Egypt) 
according to manufacturer’s manual. 
 
Collection of Umbilical Cord Blood (UCB) Samples:  
HUCB samples were obtained at the end of full-term 
vaginal deliveries of male babies after clamping and 
cutting of the cord. Ten HUCB samples were collected 
while the placenta was still in utero (Dhot et al., 2003). 
The umbilical vein was cleansed with alcohol followed 
by betadine and pierced with a sterile needle, and then 
UCB was collected into sterile collection tubes 
containing 5 ml of citrate phosphate dextrose adenine-1 
anticoagulant. UCB samples were stored at 4°C and 
processed within 24 hours of collection. 
 
Separation of Human Umbilical Cord Blood CD34+ 
Cells (HUCB CD34+ Cells): 
To isolate MNCs, each UCB unit was diluted 1:1 with 
phosphate buffer saline (PBS)/2mM EDTA. UCB was 
centrifuged at 1500 rpm for 35 min at 25°C on a layer 
of Ficoll-Hypaque solution (Sigma chemical co., USA). 
The mononuclear cell layer was obtained by a 
micropipette. The cells were incubated for 20 min at 
4°C and washed with PBS. CD34+ cells were separated 
and purified by immunomagnetic separation technique 
(Milteny, 1990) (Dynal beads Oslo Norway) according 
to the manufacturer’s instructions obtaining purity of 
approximately 97% for CD34+ cells.  Upon mixing and 
incubation, CD34+ cells bind to Dynabeads M-450 
CD34 and the rosetted cells are isolated from the 
suspension by using a DYNAL Magnetic Particle 








Concentrator (DYNAL MPC, Oslo Norway). A 
subsequent incubation with DETACHaBEAD CD34 
gently detaches isolated cells from the beads. A 
DYNAL MPC is then used to separate the purified, 
positively selected CD34+ cells from the released 
Dynabeads M-450 CD34. 
 
Isolation of Human Umbilical Cord Blood 
Mesenchymal Stem cells (HUCB MSCs): 
MSCs were recovered from HUCB by their tendency to 
adhere tightly to plastic culture dishes (Pereira et al., 
1995). Filtered HUCB cells were plated in Dulbecco's 
Modified Eagle Medium (DMEM) plus 10% fetal calf 
serum (FCS) and penicillin-streptomycin (100 U/ml to 
0.1 mg/ml) and allowed to adhere for 24 h. Non 
adherent cells were then removed. Medium was 
changed regularly every 3 days; after 2 to 3 weeks, 
adherent cells were detached by trypsin (0.25%; Lonza 
Biproducts, Belgium), washed with PBS, and used for 
the in vivo experiments. Culture and subculture of 
MSCs were carried out according to Erices et al., 
(2000) (Lonza Biproducts, Belgium) MSCs cultures 
were monitored periodically for cell detachment by 
observing the cells under the inverted microscope. 




After scarification, the two kidneys of each animal 
were removed, fixed in 10% neutral buffered formalin 
saline for 24 hours. Specimens were processed to 
paraffin sections, 5 µ thick, and then stained with 
Hematoxylin and Eosin (H & E) stain for kidneys 
general architecture evaluation, PAS stain for 
evaluation of the basement membranes & tubular brush 
borders and Immuonohistochemistry (IHC) using 
human specific anti-vimentin monoclonal mouse anti-
body for evaluation of transplanted stem cells homing. 
Twelve serial sections were taken from each block, four 
sections for each stain (H & E, PAS and IHC). 
Morphological analysis was performed to determine the 
kidney architecture, necrotic and degenerative changes. 
In addition, the extent of regeneration was also looked 
at in all slides. 
 
Statistical Analysis: 
All statistical analysis was performed using the 
statistical software package SPSS 15.0 for Windows® 
(SPSS Inc., Chicago, IL, USA). The results were 
expressed as mean ± SD. Analysis of variance 
(ANOVA) for non-parametric data was used to 
elucidate differences between all groups. Post hoc 
range tests were used to test the difference between 
each pair of means. Statistical significance level was 
defined as P < 0.05. Frequency and percentage were 
done for qualitative data. 
 
Ethical Consideration:  
The study was approved by the ethical committee of the 
Faculty of Medicine, Suez Canal University. In brief, 
the purpose of the study was explained and a written 
consent was taken from the study participants (cord 
blood donors). The used methods were safe and had no 
harm to mothers or neonates. The samples were used 
only in this study and then discarded. . Animals were 
handled gently, housed in suitable environmental 
conditions, and allowed free access to water and rat 





In day 5, both serum creatinine (Table 1) and serum 
urea (Table 2) showed a significant increment in GII, 
GIII, and GIV when compared to GI. In GII only, this 
increment progressively increased until day 25, while it 
decreased in both GIII and GIV starting from day 9. 
Afterwards, serum creatinine level showed slight 
fluctuations and a comparable level was detected in the 
last sample at day 33.  
 
 
Table 1:  
Creatinine levels in all the study groups through the study. 
Day GI GII GIII GIV P 
value 
0 0.92±.07 0.80±.16 0.82±.169 0.83±.34 NS 
5 0.87±.11 4.24±2.12" 4.02±.91" 3.64±.73" .000 
9 0.74±.11 4. 18±.16" 2.3±1.65 1.89±1.11* .020 
13 0.67±.08 5.66±1.24" 3.42±1.93 3.61±1.06 .016 
17 0.67±.10 6.07±1.13" 2.66±1.72* 3.03±1.12* .004 
21 0.98±.12 7.39±.33" 2.26±1.15* 2.476±.80* .000 
25 0.65±.07 8.23±.75 2.53±.69* 1.86±1.19* .000 
29 0.85±.10 6.73±.56" 2.43±.71* 2.4±.39* .000 
33 0.65±.06 7.76±.33" 2.005±.75* 1.94±.63* .000 
G1: Negative control, G2: Positive control, G3: MSCs Treated 
group, G4: CD 34+ Treated group. 
" Represents a statistically significant difference between the given 
group and group 1. 
* Represents a statistically significant difference between the given 












Table 2:  
Urea levels in all the study groups through the study 
Days GI GII GIII GIV P value 
0 18.5 ±2.24 17.5±2.24 19.36±2.24 18.94±2.13 NS 
5 18.75±1.43 65.6±35.98" 92.7±35.98" 76.07±14.03" .001 
9 16.87±1.17 65.2±8.79" 30.45±7.18* 30.2±10.48* .000 
13 15.67±2.34 83.43±19.17" 35.67±13.18* 32.25±14.91* .001 
17 17.88±2.20 94.54±5.02" 37.677±15.41* 43.34±9.79* .000 
21 19.87±1.42 84.23±4.43" 36.5±8.28" * 31.74±9.75* .000 
25 15.31±2.20 108.76±4.41" 35.89±13.58* 23.457±9.34* .000 
29 16.64±2.28 82.34±8.18" 26.33±8.89* 51.265±20.11* .001 
33 19.23±1.40 93.21±7.90" 61.53±26.95* 32.14±10.90* .000 
G1: Negative control, G2: Positive control, G3: MSCs Treated group, G4: CD 34+ Treated group. 
" Represents a statistically significant difference between the given group and group 1. 





Pattern of serum creatinine levels in all the study groups. GI: negative control group, GII: positive control group, GIII: MSCs 




Fig. 2:  
Pattern of serum urea levels in all the study groups. GI: negative control group, GII: positive control group, GIII: MSCs 












































Statistically significant difference was observed on 
days 13, 17, 21, 25, 29 and 33 between positive control 
and HUCB MSCs groups. HUCB CD34+ group showed 
a statistically significant difference on days 9, 17, 21, 
25, 29 and 33 as compared to positive control group. 
Regarding serum urea, statistically significant 
differences were observed at all days between positive 
control and both treatment groups. There was no 
statistically significant difference between HUCB 
CD34+ and HUCB MSCs treated groups for both serum 
creatinine and serum urea levels. The pattern of renal 
function tests in the time linear graphs are depicted in 
Figs. 1 & 2. 
 
Histopathology and immunohistochemistry: 
Histopathological examination revealed a significant 
difference between treated groups (GIII and GIV) and 
the positive control group (GII). Approximately 80 % 
of rats treated with either MSC or CD 34+ regained a 
normal nephronal architecture.  
 Kidneys of the control group (GI) showed normal 
renal architecture of both renal glomeruli, proximal and 
distal renal tubules (Fig. 3A & 4A) and negative 
reaction for human specific anti-vimentin (Fig. 5A).  
Group II showed necrotic changes of the tubular 
epithelium (Fig. 3B) with severe loss of PAS+ material 
(Fig. 4B) in 75% of the animals and negative reaction 
for human specific anti-vimentin (Fig. 5B). 
 Group III showed improvement of the proximal and 
distal tubular epithelium in 88.9% of the animals (Fig. 
3C), mild decrease in PAS+ material (Fig. 4C) and 
positive reaction for human specific anti-vimentin in 
88.9% of animals (Fig. 5C).  
 Group IV showed improvement of the proximal and 
distal tubular epithelium in 87.5% of the animals (Fig. 
3D), mild decrease in PAS+ material (Fig. 4D) and 
positive reaction for human specific anti-vimentin in 




Fig. 3:  
H&E (X400) stained sections: (Fig. A) showing renal glomerulus (G), Proximal (P) & distal (D) convoluted tubules in normal 
control group. (Fig. B) showing necrotic changes in the form of nuclear pyknosis (P), karyolysis (K) & cytoplasmic 
vacuolation (V) in positive control group. (Figs. C & D) showing improvement of the tubular epithelium in MSC and CD34+ 
treated groups, respectively. 
  











Fig. 4:  
PAS stained sections (X400), (Fig. A) showing normal PAS+ material in the brush border (*) & basement membranes of both 
proximal (P) & distal (D) convoluted tubules in normal control group. (Fig. B) showing severe decrease in PAS+ material in 
both brush borders (P) and basement membranes (B) in positive control group. (Figs. C&D) showing mild decrease in the 





   
Fig.5: IHC for human specific anti-vimentin (X400), showing negative reaction in Figs. A & B (GI & GII, respectively) and 




This study was designed to determine the comparative 
renal response to HUCB derived MSCs and CD 34+ 
stem cells transplantation in cisplatin induced ARF. We 
found significant improvement of renal function tests in 
UCB MSCs and UCB CD34+ cells treated groups in 
comparison to the positive control group starting from 
day 9. However, renal function tests in both treated 
groups were not significantly different from each other. 
In parallel to the biochemical tests the histopathological 
examination as well revealed a significant difference in 








regaining a normal nephronal architecture in both 
treated groups and they were reactive to the human 
specific anti-vimentin antibody, which provides 
evidence of homing of the transplanted cells in the 
kidney tissue of affected rats. 
  Our results are in agreement with those of Cao et al., 
(2010), who reported that the administration of UCB 
MSC led to improved renal function 16 h after 
reperfusion compared to that in control animals, as well 
as the histological changes showing recovery of tissues 
in UCB MSC treated rats. Also, Morigie et al., (2010) 
observed that infusion of UCB-MSCs in 
immunodeficient mice with cisplatin-induced acute 
kidney injury ameliorated both renal function and 
tubular cell injury, and prolonged survival. These 
results also confirm what we had reported in a previous 
study that renal function in glycerol induced ARF in 
rats improved after 4 days of HUCB CD43+ therapy 
and was restored after 2 weeks of therapy (Mohamed et 
al., 2011). 
 In this  study, the improvement of the rats' renal 
function started 9 days after injection of UCB derived 
CD 34+ and MSCs, which was similar to the results of 
Kirpatovskii et al., (2007) who found similar 
improvement after 2 weeks of kidney cells or bone 
marrow MSCs injection. They also found that kidney 
function remained normal during the remainder of the 
study period and this was also evident in our study) 
 In our study, full recovery wasn't achieved in all 
cases. This is in contrast to the results of Morigi et al., 
(2004) who found that, injection of MSCs protected 
cisplatin-treated animals from renal function 
impairment and severe tubular injury and Tögel et al., 
(2005) who demonstrated full recovery of ischemic 
ARF model within three days of MSCs administrations. 
This discrepancy may be explained by the intracarotid 
administration of MSCs to rats either immediately or 
24 hours after renal ischemia in the study of Tögel et 
al., (2005) and the early transplantation of cells in the 
study of Morigi et al., (2004) as they transplanted the 
cells one day after cisplatin injection.  
 The current study’s striking finding that HUCB-
derived stem cells significantly improved nephronal 
and proximal tubular regeneration 28 days after 
transplantation is comparable to the results of Lin et al., 
(2003) who confirmed the nephronal regeneration in 
rats with renal ischemia/reperfusion injury treated with 
BMSCs. Imberti et al., (2007) also detected 
improvement in renal structure and significant increase 
in tubular cell proliferation at 4 and 11 days post-MSC 
treatment. MSC differentiation to tubular epithelial 
cells and promotion of epithelial proliferation were also 
reported in mice with glycerol induced ARF after MSC 
therapy (Herrera et al., 2004). Recently, Morigi et al., 
(2008) observed that, human bone marrow derived 
MSCs treatment could prevent acute kidney injury 
induced by cisplatin and prolong survival in an 
immunodeficient mouse model.  
 Although Tögel et al., (2005) reported that MSCs had 
not differentiated into tubular epithelium or renal 
endothelium, suggesting that the observed beneficial 
effects had primarily been mediated via complex 
paracrine actions and not by stem cell-derived de novo 
generation of renal parenchyma, Bussolati and Camussi 
(2007) confirmed that the administered stem cells (SCs) 
may modify the microenvironment by inducing 
dedifferentiation and proliferation of tubular cells 
surviving from injury or by allowing expansion of 
resident SCs. This was confirmed in our study by the 
finding that the transplanted HUBC CD34+ cells and 
HUBC MSCs were identified by the positive reaction 
to human specific vimentin antibody. Vimentin is the 
most ubiquituos intermediate filament protein and the 
first to be expressed during cell differentiation. All 
primitive cell types express vimentin (Eriksson et al., 
1992). It is thus used as a marker for neural 
stem/progenitor cells in adult brain (Walder et al., 
2003). Recent studies show that renal tissue–derived 
CD133 positive cells express vimentin before they fully 
differentiate into epithelial cells (Bussolati et al., 2005). 
The anti-Human Vimentin Antibody was screened on a 
human mesenchymal stem cell line and on human 
fibroblast cells by immunocytochemistry (Lee et al., 
2006). 
  The exact mechanism through which MSCs mitigate 
renal damage is not fully elucidated. One possible 
explanation is that MSCs produce cytokines and growth 
factors that promote anti-inflammatory, 
immunosuppressive, anti-apoptotic and proliferative 
effects (Humphreys and Bonventre, 2008). Recently, 
Huls et al., (2010) revealed that, bone marrow derived 
MSCs may have the capacity to migrate to the injured 
kidney and contribute to tubule epithelium regeneration 
and renal function repair without fusing with resident 
tubular cells. Finally, Togel and Westenfelder (2011) 
proposed that MSCs must provide paracrine and/or 
endocrine factors that explain their positive effects on 
kidney repair following injury. 
 Theoretically MSCs have a better capacity for self-
renewal while maintaining their multipotency (Engler 
et al., 2006). They are also a better candidate for renal 
repair, because nephrons are of mesenchymal origin 
(Rayan et al., 2005) which is proved in our study. 
MSCs have a better immunomodulatory effect by virtue 
of avoiding allorecognition, interference with T cell 
function and generation of local immunosuppressive 
microenvironment by secreting cytokines. Ryan et al., 
(2005) also concluded that the immunomodulatory 








function of MSCs is enhanced when the cells are 
exposed to an inflammatory environment. All of these 
may explain the absence of rejection to HUCB stem 
cells (Castillo et al., 2007).                                                    
 One of the weaknesses of this study is that changes in 
nephronal architecture were not followed every 4 days 
and correlated with renal function tests. This would 
have required a large number of rats to be sacrificed). 
 In conclusion, HUCB derived MSCs or CD34+ cells 
have induced renal improvement to a comparable 
degree in a rat model of cisplatin induced acute renal 
failure. Thus, HUCB can provide a novel source of 
cells for stem cell-based therapies. It may help develop 
improved therapies for renal failure with the capacity to 
replace a wide range of the kidney's functions, thereby 
reducing morbidity, mortality, and the economic impact 
associated with this disease. 
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